Atea Pharmaceuticals (AVIR) EPS (Weighted Average and Diluted) (2020 - 2022)
Historic EPS (Weighted Average and Diluted) for Atea Pharmaceuticals (AVIR) over the last 3 years, with Q4 2022 value amounting to -$0.41.
- Atea Pharmaceuticals' EPS (Weighted Average and Diluted) fell 13106.06% to -$0.41 in Q4 2022 from the same period last year, while for Dec 2022 it was -$1.4, marking a year-over-year decrease of 20447.76%. This contributed to the annual value of -$2.0 for FY2024, which is 2269.94% down from last year.
- Latest data reveals that Atea Pharmaceuticals reported EPS (Weighted Average and Diluted) of -$0.41 as of Q4 2022, which was down 13106.06% from -$0.1 recorded in Q3 2022.
- In the past 5 years, Atea Pharmaceuticals' EPS (Weighted Average and Diluted) ranged from a high of $2.62 in Q4 2020 and a low of -$1.74 during Q3 2020
- Over the past 3 years, Atea Pharmaceuticals' median EPS (Weighted Average and Diluted) value was -$0.34 (recorded in 2021), while the average stood at -$0.02.
- In the last 5 years, Atea Pharmaceuticals' EPS (Weighted Average and Diluted) skyrocketed by 10202.02% in 2021 and then plummeted by 200000.0% in 2022.
- Quarter analysis of 3 years shows Atea Pharmaceuticals' EPS (Weighted Average and Diluted) stood at $2.62 in 2020, then plummeted by 49.62% to $1.32 in 2021, then plummeted by 131.06% to -$0.41 in 2022.
- Its EPS (Weighted Average and Diluted) was -$0.41 in Q4 2022, compared to -$0.1 in Q3 2022 and -$0.38 in Q2 2022.